GeneDx (WGS), Zevra Therapeutics (ZVRA) Partner to Launch Sponsored Genetic Testing Program for NPC

GeneDx Holdings Corp. (NASDAQ:WGS) is one of the most promising stocks under $100 to buy. On March 10, GeneDx and Zevra Therapeutics (NASDAQ:ZVRA) announced a new partnership to launch a sponsored genetic testing program for NPC (Niemann-Pick disease type C). This aims to expand access to GeneDx’s ExomeDx test for patients in the US who are suspected of having this rare, inherited condition. By providing high-quality exome sequencing at no charge to eligible patients, the program seeks to help clinicians confirm diagnoses more quickly and guide informed clinical decision-making.

The program addresses the challenges of NPC, which is a progressive neurodegenerative disorder caused by mutations in the NPC1 and NPC2 genes. Because the disease often presents with symptoms that overlap with other metabolic or neurological conditions, diagnosis is frequently delayed. This collaboration focuses on removing barriers to genomic testing, allowing healthcare providers to receive results in as little as 3 weeks. Identifying patients earlier is considered a critical step in managing the disease and ensuring access to appropriate therapies as they emerge.

De-identified data from the testing program will be integrated into GeneDx Infinity, which is a large rare-disease genomic dataset. This integration is intended to help biopharmaceutical partners better understand disease biology and accelerate the journey from diagnosis to treatment. Zevra Therapeutics is providing financial support for the program, reflecting a joint commitment to using genomic insights to improve outcomes for individuals and families affected by NPC.

Photo by National Cancer Institute on Unsplash

GeneDx Holdings Corp. (NASDAQ:WGS) is a genomics company in the healthcare industry. It provides genetic testing services and provides pediatric & rare disease diagnostics.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None.  Follow Insider Monkey on Google News.